Valuation : Caplin Point Laboratories Limited

Market Cap 212B 2.22B 1.91B 1.8B 1.64B 3.07B 3.1B 21.46B 8.26B 108B 8.34B 8.16B 342B P/E 2027 *
29.2x
P/E 2028 * 25.2x
Enterprise Value 212B 2.22B 1.91B 1.8B 1.64B 3.07B 3.1B 21.46B 8.26B 108B 8.34B 8.16B 342B EV / Sales 2027 *
8.47x
EV / Sales 2028 * 7.49x
Free-Float
26.56%
Yield 2027 *
0.14%
Yield 2028 * 0.14%
1 day+2.66%
1 week+2.75%
Current month+11.04%
1 month+8.60%
3 months+23.95%
6 months+67.33%
Current year+52.08%
1 week 2,707.7
Extreme 2707.7
2,850.4
1 month 2,382.5
Extreme 2382.5
2,877.3
Current year 1,500.3
Extreme 1500.3
2,877.3
1 year 1,500.3
Extreme 1500.3
2,877.3
3 years 954
Extreme 954
2,877.3
5 years 575
Extreme 575
2,877.3
10 years 176.2
Extreme 176.2
2,877.3
Manager TitleAgeSince
Chief Executive Officer 71 28/03/2015
Director of Finance/CFO - 19/02/2016
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 73 27/01/2010
Director/Board Member - 05/11/2025
Director/Board Member 71 28/03/2015
Change 5-day change 1-year change 3-year change Capi.($)
+2.66%+2.75% - - 2.18B
-0.21%-3.66%+16.92%+64.62% 47.02B
-1.80%-5.95%+34.69%+111.80% 39.94B
-0.85%-3.15%+7.94%+77.95% 11.82B
+0.75%-2.80%-11.49%+10.34% 11.57B
0.00%+0.19%+19.18%+137.27% 9.18B
-0.40%-5.12%+34.30%-16.30% 7.2B
-0.82%-1.83%+14.11%+210.87% 7.22B
-0.72%-2.42%+20.10%+32.94% 7.32B
-1.43%-1.34%-44.42%+21.01% 5.2B
Average -0.28%-2.68%+10.15%+72.28% 16.28B
Weighted average by Cap. -0.66%-3.26%+17.63%+78.93%

Financials

2027 *2028 *
Net sales 25.07B 262M 226M 213M 194M 362M 366M 2.53B 975M 12.72B 985M 963M 40.39B 28.34B 296M 255M 241M 219M 410M 413M 2.86B 1.1B 14.37B 1.11B 1.09B 45.66B
Net income 7.26B 75.98M 65.34M 61.65M 56.17M 105M 106M 734M 283M 3.68B 285M 279M 11.7B 8.41B 87.97M 75.66M 71.38M 65.03M 122M 123M 850M 327M 4.27B 330M 323M 13.55B
Net Debt - -
Logo Caplin Point Laboratories Limited
Caplin Point Laboratories Limited is an India-based pharmaceutical company with a business model catering predominantly to emerging markets of Latin America and Africa. The Company has also entered regulated markets such as the United States through its Subsidiary, Caplin Steriles Limited. The Company's operations include research & development and manufacturing of finished formulations, active pharmaceutical ingredients (APIs), clinical research, front-end generic presence in Latin America, brand marketing in Francophone Africa and a USFDA/EU-GMP approved injectable facility. In the Regulated Markets, its products include liquid & lyophilized vials, pre-filled syringes, three-pc ophthalmic droppers and pre-mix bags. In the Emerging Markets, its products include tablets, dry syrups - bottles, soft gels, capsules, suppositories, liquid syrups - bottles, liquid injectables in ampoules & vials, lyophilized vials, prefilled syringes (PFS), and emulsion injection in ampoules & vials.
Employees
3,966
Date Price Change Volume
10/09/26 2,795.40 +2.66% 245,863
09/09/26 ₹2,723.10 -1.70% 117,200
08/09/26 ₹2,770.10 -1.56% 127,691
07/09/26 ₹2,814.00 +0.11% 111,399
04/09/26 ₹2,810.80 -1.20% 208,526
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2,793.00INR
Average target price
2,765.00INR
Spread / Average Target
-1.00%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!